Patenting drugs developed with artificial intelligence is running into a legal minefield. Even as AI transforms the pharma industry at breakneck speed, intellectual property questions remain up in the air.

Legal headaches for patenting AI drugs

Using AI to discover new drug compounds is quickly becoming the norm. But patent law isn't always ready for this kind of disruption. The biggest sticking point? Figuring out who counts as the inventor. Traditional patent systems only recognize humans or teams of people as inventors—AI algorithms aren’t considered legal entities, so they can't hold rights.

Risks for pharma companies

Without clear legal frameworks, pharma companies risk losing their exclusive rights to new discoveries. That uncertainty could slow down the rollout of AI-designed drugs and make the whole sector less attractive to investors.

No global consensus in sight

There’s still no worldwide agreement on how to patent AI-generated drugs. Lawmakers in different countries interpret the role of AI in invention in their own ways, creating a patchwork of rules that makes it tough to protect intellectual property across borders.